Archive

ECCO 2016: Professor David Rubin from Chicago discusses the challenges of UC management and optimising biological therapy

Management of ulcerative colitis: putting patients at the centre – by Maria Dalby Iris Dotan (Tel Aviv Sourasky Medical Centre, Israel), Peter Irving (Guy’s and St Thomas’ NHS… read more.

ECCO 2016: Professor Séverine Vermeire (Leuven, Belgium) discusses new patient guidelines for Crohn’s disease and ulcerative colitis which were released at this year’s 11th Congress of ECCO in Amsterdam, and Helen Terry (CCUK) discusses how they might be rolled out to patients in the UK.

ECCO-EFCCA Patient Guidelines – by Maria Dalby Marco Greco, Milan, Italy; Séverine Vermeire, University Hospital of Leuven, Belgium; Salvatore Leone, Palermo, Italy; Paolo Gionchetti, University of Bologna, Italy; Martin Kojinov, Sofia, Bulgaria; Axel… read more.

Herceptin plus lapatinib shows “amazing” potential in breast cancer

by Bruce Sylvester: Researchers report that Herceptin (trastuzamab) plus lapatinib can shrink breast cancer tumors in less than two weeks. The findings were reported in March at the… read more.

For grade 2 glioma, radiation plus chemo betters radiation alone

by Bruce Sylvester: Patients with grade 2 glioma who received radiation therapy plus PCV chemotherapy (procarbazine, lomustine and vincristine) have achieved longer progression-free survival and overall survival than… read more.

BTS 2016: Controversies in UK organ transplantation: have we gone too far in terms of organ quantity at the expense of organ quality? Professor Derek Manas (Newcastle upon Tyne) and Lorna Marson (Edinburgh) discuss in this video the plenary on quantity vs quality.

Controversies in UK organ transplantation: have we gone too far in terms of organ quantity at the expense of organ quality? John Forsythe, Edinburgh Royal Infirmary and Chris… read more.

BTS 2016: Should patients with non-HCC related cancers be considered for listing for liver transplantation in the UK? An interview with Professor Nigel Heaton, who was Judge, and Dr Varuna Aluvihare (both from Kings College Hospital, London), who was Juror in this session

World Health Matters: Italy: Leukaemia death rate expected to fall in 2016

by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.

ASH 2015: Ernest Beutler Lecture Prize: Award-winners trace history of proteasome and its starring role in MM treatment: Interview with Alfred Goldberg, PhD, Professor of Cell Biology at Harvard Medical School, and Paul Richardson, MD, Professor of Medicine at the Dana-Farber Cancer Center

by Thomas R. Collins: Standing at the center of a decade and a half of stunning advancements in the treatment of multiple myeloma is the ubiquitin proteasome pathway… read more.

Increased risk of diabetes appears in women with sleep problems

by Bruce Sylvester: Women who have problems sleeping are at an increased risks of developing type 2 diabetes, researchers reported on January 28, 2016 in Diabetologia.

ASH 2015: TOURMALINE: Professor Philippe Moreau (University Hospital, Nantes, France) discusses the Tourmaline study – ixazomib, lenalidomide, dexamethasone (iRd) in R/R myeloma, with opinions on the data from Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK), Professor Gordon Cook (Leeds Teaching Hospitals, UK), Erik Low (Chief Executive Myeloma UK) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA)

Ixazomib improves progression-free survival across subgroups by Thomas R. Collins: The oral proteasome inhibitor (PI) ixazomib with lenalidomide and dexamethasone (IRd) performed well versus placebo plus lenalidomide and… read more.

ASH 2015: Clinical discussant in this ASH/FDA session, Professor Paul Richardson (Harvard medical School, Boston, USA), discusses the clinical relevance of the new oral proteazome inhibitor ixazomib and two new monoclonal antibodies daratumumab and elotuzumab approved in the last few weeks by the FDA

Experts try to provide clarity in dizzying myeloma landscape by Thomas R. Collins: There’s no doubt that the bonanza of new multiple myeloma therapies is a blessing to… read more.

ASH 2015: New therapies explored in peripheral T-cell lymphoma

by Thomas R. Collins: In early results, patients newly diagnosed with peripheral T-cell lymphoma (PTCL) treated with the HDAC-inhibitor belinostat, and CHOP therapy, tolerated the combination well at… read more.